
Quarterly report 2024-Q1
added 05-06-2024
ShockWave Medical EBITDA 2011-2026 | SWAV
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA ShockWave Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 169 M | 129 M | 2.71 M | -63.8 M | -49.6 M | -40.5 M | -30.4 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 169 M | -63.8 M | 16.7 M |
Quarterly EBITDA ShockWave Medical
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.5 M | - | - | 41.5 M | - | 40.1 M | 31.6 M | 16.3 M | - | 5.5 M | 1.42 M | -16.8 M | - | -11.4 M | -17.1 M | -18.6 M | - | -12.2 M | -10.7 M | -11.9 M | - | -9.61 M | -9.91 M | -9.67 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 45.5 M | -18.6 M | 3.18 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ClearPoint Neuro
CLPT
|
-23.4 M | $ 11.64 | -8.85 % | $ 330 M | ||
|
EDAP TMS S.A.
EDAP
|
-18 M | $ 4.17 | 0.97 % | $ 156 M | ||
|
Apyx Medical Corporation
APYX
|
-5.79 M | $ 4.05 | -7.11 % | $ 166 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
-13.6 M | - | - | $ 3.31 B | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
-4.64 M | $ 7.66 | 1.19 % | $ 1.15 B | ||
|
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | ||
|
BioSig Technologies
BSGM
|
-67.6 M | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.3 | -3.77 % | $ 1.4 M | ||
|
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 17.72 | -1.01 % | $ 416 M | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
LENSAR
LNSR
|
-21 M | $ 5.54 | -4.97 % | $ 66.2 M | ||
|
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | ||
|
Pulmonx Corporation
LUNG
|
-52.6 M | $ 1.27 | -5.22 % | $ 51.7 M | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
Cytosorbents Corporation
CTSO
|
-13.5 M | $ 0.5 | -8.16 % | $ 31.1 M | ||
|
LivaNova PLC
LIVN
|
228 M | $ 70.0 | -2.33 % | $ 3.82 B | ||
|
MiMedx Group
MDXG
|
78.8 M | $ 3.56 | 0.28 % | $ 526 M | ||
|
Delcath Systems
DCTH
|
898 K | $ 11.07 | -3.4 % | $ 397 M | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
IRIDEX Corporation
IRIX
|
-2.05 M | $ 1.01 | - | $ 17.1 M | ||
|
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | ||
|
Myomo
MYO
|
-13.5 M | $ 0.91 | 2.49 % | $ 38.1 M | ||
|
Orthofix Medical
OFIX
|
-4.11 M | $ 12.01 | -2.28 % | $ 476 M | ||
|
Electromed
ELMD
|
10.7 M | $ 35.68 | -2.25 % | $ 302 M | ||
|
Butterfly Network
BFLY
|
-79.7 M | $ 3.83 | -6.59 % | $ 811 M | ||
|
Insulet Corporation
PODD
|
564 M | $ 147.46 | -0.82 % | $ 10.4 B | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
-27.1 M | - | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
-9.67 M | - | -0.57 % | $ 7.12 M | ||
|
Sintx Technologies
SINT
|
-10.4 M | $ 2.27 | -5.62 % | $ 6.3 M | ||
|
Globus Medical
GMED
|
757 M | $ 76.64 | -0.74 % | $ 10.4 B | ||
|
Profound Medical Corp.
PROF
|
-40.9 M | $ 6.97 | -3.19 % | $ 211 M | ||
|
Stryker Corporation
SYK
|
6.46 B | $ 306.76 | 0.41 % | $ 117 B | ||
|
CONMED Corporation
CNMD
|
120 M | $ 35.49 | -2.34 % | $ 1.1 B | ||
|
Tactile Systems Technology
TCMD
|
35.9 M | $ 22.74 | -1.3 % | $ 520 M | ||
|
Inspire Medical Systems
INSP
|
64.9 M | $ 40.05 | -6.12 % | $ 1.18 B | ||
|
Tandem Diabetes Care
TNDM
|
26 M | $ 12.82 | -9.4 % | $ 872 M |